JayHTraverseMD
Cardiology • Minneapolis, MNInterventional Cardiology
Associate Professor, Medicine, University of Minnesota Medical School, Minneapolis
Dr. Traverse is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 E 28th St
Minneapolis, MN 55407Phone+1 612-775-3030Fax+1 612-863-3784
Summary
- Dr. Jay Traverse is a cardiologist in Minneapolis MN and is affiliated with multiple hospitals in the area, including Abbott Northwestern Hospital and New Ulm Medical Center. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 28 years. He specializes in interventional cardiology and is experienced in interventional cardiology, cardiac catheterization, and percutaneous coronary intervention.
Education & Training
University of MinnesotaFellowship, Cardiovascular Disease, 1992 - 1996- University of MinnesotaResidency, Internal Medicine, 1989 - 1992
Case Western Reserve University School of MedicineClass of 1989
University of Notre DameBS, Chemical Engineering- University of VirginiaME, Biomedical Engineering
Certifications & Licensure
MN State Medical License 1991 - 2025- American Board of Internal Medicine Interventional Cardiology
- National Board of Physicians and Surgeons Cardiovascular Disease
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Interventional Cardiology
Awards, Honors, & Recognition
- FAHA American Heart Assiciation
- FSCAI Society for Coronary Angiography and Interventions
- Vice Chairman of Cardiology Abbott Northwestern Hospital
- Join now to see all
Clinical Trials
- Bone Marrow Stem Cell Infusion Following a Heart Attack Start of enrollment: 2005 Dec 01
- Post-conditioning to Reduce Infarct Size Start of enrollment: 2008 Sep 01
- IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 73 citationsIntracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial.Raj Makkar, Dean J. Kereiakes, Frank V. Aguirre, Glenn Kowalchuk, Tarun Chakravarty
European Heart Journal. 2020-09-21 - 154 citationsFirst-in-Man Study of a Cardiac Extracellular Matrix Hydrogel in Early and Late Myocardial Infarction Patients.Jay H. Traverse, Timothy D. Henry, Nabil Dib, Amit N. Patel, Carl J. Pepine
JACC. Basic to Translational Science. 2019-09-11 - 565 citationsImpact of Atrial Fibrillation on the Clinical Course of Hypertrophic CardiomyopathyIacopo Olivotto, Franco Cecchi, Susan A. Casey, Alberto Dolara, Jay H. Traverse
Circulation. 2002-05-01
Journal Articles
- Prevalence, Trends, and Outcomes of Higher Risk Percutaneous Coronary Interventions Among Patients Without Acute Coronary Syndromes☆☆☆Ivan Chavez, M Nicholas Burke, Daniel Lips, Jay Traverse, Emmanouil S Brilakis, Anil Poulose, Michael Mooney, Paul Sorajja, Yale Wang, ScienceDirect
- Meta‐Analysis of the Impact of Successful Chronic Total Occlusion Percutaneous Coronary Intervention on Left Ventricular Systolic Function and Reverse RemodelingIvan Chavez, Yale Wang, Emmanouil S Brilakis, Louis P Kohl, Daniel Lips, Michael Mooney, Paul Sorajja, Anil Poulose, M Nicholas Burke, Jay Traverse, Journal of Interventional Cardiology
Press Mentions
Minneapolis Heart Institute Foundation Completes First Enrollment in Research to Evaluate Evidence with SuperSaturated Oxygen (SSO2) Therapy in Reducing Heart Failure and MortalitySeptember 23rd, 2024- Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionMay 10th, 2022
- Novel Hydrogel May Help Repair Cardiac TissueJuly 9th, 2020
- Join now to see all
Grant Support
- Cardiovascular Cell Therapy Research Network (CCTRN)NHLBI2012–Present
- Phase II Clinical Trial of Postconditions in patients with ST- Elevation Myocardial InfarctionNHLBI2011–Present
Professional Memberships
- Fellow
- American Physiological SocietyMember
- Fellow
- Society for Coronary Angiography and InterventionsFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
